

THE UNITED STATES PATENT AND TRADEMARK OFFICE (Attorney Docket No. AM100221)

14.75	10 EMARK		
In re Patent Application of:)	Appln. No.: 09/887,296
)	Confirmation No.: 6853
	HSIEN-JUE (STEVE) CHU et al.)	Customer No.: 25291
)	Group Art Unit: 1645
Filed:	06/21/2001)	Examiner: S. Devi, Ph.D.
)	
For:	METHODS AND COMPOSITION)	
	FOR ORAL VACCINATIONS)	

SECOND AMENDMENT AFTER FINAL REJECTION PURSUANT TO 37 C.F.R. § 1.116

Dear Sir:

Responsive to the Advisory action mailed September 7, 2005, please amend the above application according to the below instructions and consider the remarks in a positive light.

REMARKS

Reconsideration of this application, as amended, is respectfully requested.

Applicants understand that they cannot amend the finally rejected claims as a matter of right. However, since the Examiner did not enter the last amendment, the present amendment is warranted in a good faith attempt to overcome the rejections of Claims 2 and 3 under 35 U.S.C. § 112, second paragraph, to persuade the Examiner that the claimed invention is unique in view of the cited art and to correct obvious typographical or clerical errors. Therefore, the amendment is needed for either allowance or removal of issues on appeal.

With respect to the rejections under 35 U.S.C. § 112, second paragraph, Claim 2 has been canceled and Claim 3 has been amended for the better readability thereof. Amended Claim 3 omits "or the disease caused by the antigen" and, instead, lists the well-known viral antigens that correspond to certain clinical or medical conditions or diseases to which the Examiner had referred under paragraph (f) of the Office action mailed 09/10/04.

As a consequence of amending Claim 3, obvious typographical or clerical errors came to light in that the terms "Feline rhinotrachelitis" and "cauidiosis" should read "Feline

Page 1 of 11

ANNE M. ROSENBLUM ATTORNEY AT LAW

163 DELAWARE AVENUE - SUITE 212 • DELMAR, NEW YORK 12054 • TELEPHONE: (518) 475-0611

1000 mg/s/05